MA55517A - Composés macrocycliques utilisés en tant qu'agonistes sting - Google Patents

Composés macrocycliques utilisés en tant qu'agonistes sting

Info

Publication number
MA55517A
MA55517A MA055517A MA55517A MA55517A MA 55517 A MA55517 A MA 55517A MA 055517 A MA055517 A MA 055517A MA 55517 A MA55517 A MA 55517A MA 55517 A MA55517 A MA 55517A
Authority
MA
Morocco
Prior art keywords
compounds used
macrocyclic compounds
sting agonists
sting
agonists
Prior art date
Application number
MA055517A
Other languages
English (en)
Inventor
Moloy Banerjee
Vaibhav Madhukar Kalhapure
Rajender Kumar Kamboj
Navnath Popat Karche
Venkata P Palle
Pradeep Rangrao Patil
Vidya Ramdas
Vinod Popatrao Vyavahare
Deepak Sahebrao Walke
Original Assignee
Lupin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lupin Ltd filed Critical Lupin Ltd
Publication of MA55517A publication Critical patent/MA55517A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/16—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
MA055517A 2019-03-28 2020-03-21 Composés macrocycliques utilisés en tant qu'agonistes sting MA55517A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201921012258 2019-03-28
IN201921046194 2019-11-13

Publications (1)

Publication Number Publication Date
MA55517A true MA55517A (fr) 2022-02-09

Family

ID=70293003

Family Applications (1)

Application Number Title Priority Date Filing Date
MA055517A MA55517A (fr) 2019-03-28 2020-03-21 Composés macrocycliques utilisés en tant qu'agonistes sting

Country Status (20)

Country Link
US (1) US20220144852A1 (fr)
EP (1) EP3946610A1 (fr)
JP (1) JP7530380B2 (fr)
KR (1) KR20210146370A (fr)
CN (1) CN113631228B (fr)
AU (1) AU2020245263B2 (fr)
BR (1) BR112021018947A2 (fr)
CA (1) CA3132508A1 (fr)
CL (1) CL2021002480A1 (fr)
CO (1) CO2021012559A2 (fr)
CR (1) CR20210495A (fr)
EC (1) ECSP21071644A (fr)
IL (1) IL286526A (fr)
MA (1) MA55517A (fr)
MX (1) MX2021011686A (fr)
PE (1) PE20220169A1 (fr)
PH (1) PH12021552263A1 (fr)
SG (1) SG11202109191SA (fr)
WO (1) WO2020194160A1 (fr)
ZA (1) ZA202106629B (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GEP20247627B (en) 2019-07-22 2024-05-27 Lupin Ltd Macrocyclic compounds as sting agonists and methods and uses thereof
KR20220056176A (ko) 2019-08-02 2022-05-04 메르사나 테라퓨틱스, 인코포레이티드 암 치료를 위한 sting(인터페론 유전자의 자극인자) 작용제로서의 비스-[n-((5-카바모일)-1h-벤조[d]이미다졸-2-일)-피라졸-5-카복사미드] 유도체 및 관련 화합물
AU2021248635B2 (en) 2020-04-02 2025-10-23 Mersana Therapeutics, Inc. Antibody drug conjugates comprising STING agonists
EP4134098A4 (fr) 2020-04-10 2024-05-15 ONO Pharmaceutical Co., Ltd. Méthode de cancérothérapie
AU2022208054A1 (en) * 2021-01-15 2023-07-27 Seagen Inc. Immunomodulatory antibody-drug conjugates
AR133266A1 (es) * 2023-07-19 2025-09-10 Hoffmann La Roche Macrociclos para el tratamiento de enfermedades autoinmunitarias

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104513253A (zh) * 2013-10-01 2015-04-15 南京波尔泰药业科技有限公司 用于治疗增殖性疾病的大环化合物
KR20170109546A (ko) * 2015-02-05 2017-09-29 메르크 파텐트 게엠베하 Irak1/4 억제제로서의 매크로시클릭 화합물 및 이들의 용도
US10844051B2 (en) 2015-07-22 2020-11-24 The Royal Institution For The Advancement Of Learning/Mcgill University Substituted oxazoles for the treatment of cancer
AR107032A1 (es) 2015-12-09 2018-03-14 Padlock Therapeutics Inc Inhibidores bicíclicos de pad4
PE20181884A1 (es) * 2016-04-07 2018-12-07 Glaxosmithkline Ip Dev Ltd Amidas heterociclicas utiles como moduladores de proteinas
ES2781474T3 (es) 2016-04-07 2020-09-02 Glaxosmithkline Ip Dev Ltd Amidas heterocíclicas útiles como moduladores de proteínas
JP2020524717A (ja) 2017-06-22 2020-08-20 キュラデブ・ファーマ・リミテッドＣｕｒａｄｅｖ Ｐｈａｒｍａ Ｌｉｍｉｔｅｄ ヒトｓｔｉｎｇの小分子調節因子
CN111132972B (zh) 2017-06-22 2024-07-12 克拉德夫制药有限公司 人sting的小分子调节剂
US20200172483A1 (en) 2017-06-22 2020-06-04 Curadev Pharma Limited Heterocyclic small molecule modulators of human sting
EP3658138B1 (fr) 2017-07-27 2023-04-19 Stingray Therapeutics, Inc. Série de 3 h-imidazo(4,5-c)pyridine substituée et de 1h-pyrrolo(2,3-c)pyridine d'une nouvelle ectonucléotide pyrophosphatase/phosphodiestérase-1 (enpp1) et stimulateur pour un modulateur de gènes d'interféron (sting) en tant qu'agents immunothérapeutiques contre le cancer
JP2020530838A (ja) 2017-08-04 2020-10-29 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． がん治療のためのベンゾ［ｂ］チオフェンＳＴＩＮＧアゴニスト
WO2019027857A1 (fr) * 2017-08-04 2019-02-07 Merck Sharp & Dohme Corp. Combinaisons d'antagonistes de pd-1 et d'agonistes de sting benzo[b]thiophéniques pour le traitement du cancer

Also Published As

Publication number Publication date
ZA202106629B (en) 2022-07-27
EP3946610A1 (fr) 2022-02-09
JP7530380B2 (ja) 2024-08-07
PH12021552263A1 (en) 2022-07-11
CA3132508A1 (fr) 2020-10-01
SG11202109191SA (en) 2021-09-29
PE20220169A1 (es) 2022-01-28
JP2022527306A (ja) 2022-06-01
CL2021002480A1 (es) 2022-04-29
MX2021011686A (es) 2021-10-22
CN113631228B (zh) 2023-10-13
CR20210495A (es) 2021-10-18
CO2021012559A2 (es) 2021-09-30
US20220144852A1 (en) 2022-05-12
AU2020245263A1 (en) 2021-10-07
ECSP21071644A (es) 2021-12-30
CN113631228A (zh) 2021-11-09
AU2020245263B2 (en) 2025-07-03
IL286526A (en) 2021-10-31
KR20210146370A (ko) 2021-12-03
BR112021018947A2 (pt) 2022-02-08
WO2020194160A1 (fr) 2020-10-01

Similar Documents

Publication Publication Date Title
MA52189A (fr) Benzothiophènes et composés associés utilisés en tant qu'agonistes de sting
MA55517A (fr) Composés macrocycliques utilisés en tant qu'agonistes sting
EP3621624A4 (fr) Composés dinucléotidiques cycliques en tant qu'agonistes sting
MA52754A (fr) Composés hétérocycliques tricycliques en tant qu'activateurs de sting
MA55198A (fr) Composés tricycliques fusionnés utiles en tant qu'agents anticancéreux
MA56398A (fr) Composés 2,3-dihydroquinazoline en tant qu'inhibiteurs de nav1.8
EP3768661A4 (fr) Composés deutérés utilisés en tant qu'inhibiteurs de rock
EP3873468A4 (fr) 2-amino-n-phényl-nicotinamides utilisés en tant qu'inhibiteurs de nav1.8
MA53377A (fr) Composés de pyridin-2-one utiles en tant qu'antagonistes de smarca2
MA49888A (fr) Composés macrocycliques utilisés en tant qu'inhibiteurs de kinase ros1
MA53220A (fr) Nouveaux composés hétérocycliques utilisés en tant qu'inhibiteurs de monoacylglycérol lipase
MA45375A (fr) Composés hétérocycliques utilisés en tant qu'agents antibacteriens
MA52486A (fr) Pyridazinones utilisés en tant qu'inhibiteurs de parp7
MA46452A (fr) Composés de benzo[b]thiophéne en tant qu'agonistes de sting
MA43169A (fr) Composés hétérocycliques utilisés en tant qu'inhibiteurs de pi3k-gamma
EP3344644A4 (fr) Composés di-nucléotidiques cycliques en tant qu'agonistes de sting
MA51327A (fr) Composés cycliques fusionnés en 5,5 à substitution diaryle, utilisés en tant qu'inhibiteurs du c5ar
MA47099A (fr) Composés hétéroaromatiques bicycliques utilisés en tant qu'immunomodulateurs
MA49374A (fr) Composés hétéroaromatiques utilisés en tant qu'inhibiteurs de vanine
MA54378A (fr) Composés hétéroaromatiques utilisés en tant qu'inhibiteurs de vanine
MA51438A (fr) Composés hétérocycliques utilisés en tant qu'inhibiteurs de lsd1
MA46955A (fr) Nouveaux composés en tant qu'agonistes récepteurs de glp1/glucagon/gip trigonal peptidique
EP3752144A4 (fr) Composés hétérocycliques tricycliques utiles en tant qu'inhibiteurs de l'intégrase du vih
MA52367A (fr) Composés hétérocycliques tricycliques utiles en tant qu'inhibiteurs de l'intégrase du vih
MA53479A (fr) Composés hétérocycliques en tant q'inibiteurs de vanin